Skip to content

ALA on Glycemic Control in T2DM Participants

The Effect of Alpha-Linolenic Acid on Glycemic Control in Participants With Type 2 Diabetes

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02701894
Enrollment
200
Registered
2016-03-08
Start date
2012-12-31
Completion date
2016-03-31
Last updated
2016-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

With the emerging worldwide epidemic of type 2 diabetes, dietary recommendations to improve diabetes management have been emphasized in the scientific community. Particular attention has been drawn to various benefits of replacing saturated fatty acids with unsaturated fatty acids. Alpha-linolenic acid, the only omega-3 fatty acid that is from plant sources, has been suggested by animal and cell studies to play a beneficial role in regulating blood glucose levels. However, human studies have been more inconsistent with their findings. The focus of this project is to investigate the evidence in the context of ALA and blood glucose parameters in participants with type 2 diabetes by conducting a systematic review and meta-analysis of randomized controlled trials.

Interventions

DIETARY_SUPPLEMENTAlpha-Linolenic Acid

Meta-Analysis of Randomized Controlled Trials

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Study design

Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Controlled, randomized, clinical trials * Trials greater than one month * Focusing on ALA and T2DM participants * Viable endpoint data

Exclusion criteria

* Non-human studies * Non-random treatment allocation * Less than 1 month * Lack of suitable control * Lack of endpoint data

Design outcomes

Primary

MeasureTime frame
HbA1c1 month

Secondary

MeasureTime frame
Fructosamine1 month
Fasting Blood Glucose1 month
Fasting Blood Insulin1 month
Glycated Albumin1 month
HOMA- IR1 month

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026